SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Silexion Therapeutics Corp
Date: Sept. 29, 2025 · CIK: 0002022416 · Accession: 0000000000-25-010616

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-290544

Date
September 29, 2025
Author
Division of
Form
UPLOAD
Company
Silexion Therapeutics Corp

Letter

Re: Silexion Therapeutics Corp Registration Statement on Form S-3 Filed September 26, 2025 File No. 333-290544 Dear Ilan Hadar:

September 29, 2025

Ilan Hadar Chief Executive Officer Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan, Israel 5250606

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Gary Emmanuel

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 September 29, 2025

Ilan Hadar
Chief Executive Officer
Silexion Therapeutics Corp
12 Abba Hillel Road
Ramat Gan, Israel 5250606

 Re: Silexion Therapeutics Corp
 Registration Statement on Form S-3
 Filed September 26, 2025
 File No. 333-290544
Dear Ilan Hadar:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Jason Drory at 202-551-8342 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Gary Emmanuel
</TEXT>
</DOCUMENT>